#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Competing priorities and second chances - A qualitative exploration of prisoners’ journeys through the Hepatitis C continuum of care


Autoři: Desmond Crowley aff001;  Walter Cullen aff002;  John S. Lambert aff002;  Marie Claire Van Hout aff004
Působiště autorů: Irish College of General Practitioners, Lincoln Place, Dublin, Ireland aff001;  School of Medicine, University College Dublin, Dublin, Ireland aff002;  Department of Infectious Diseases, Mater Misericordiae University Hospital, Dublin, Ireland aff003;  Liverpool John Moores University, Liverpool, United Kingdom aff004
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0222186

Souhrn

High levels of undiagnosed and untreated HCV infection exist in prison populations globally. Prisons are a key location to identify, treat and prevent HCV infection among people who inject drugs (PWID). Understanding prisoners’ lived experiences of the HCV continuum of care informs how HCV care can be effectively delivered to this marginalised and high-risk population. This study aimed to explore Irish prisoners’ experience of prison and community-based HCV care. We conducted one-to-one interviews with 25 male prisoners with chronic HCV infection. Data collection and analysis was informed by grounded theory. The mean age of participants and first incarceration was 39.5 and 18.3 years respectively. The mean number of incarcerations was eight. The following themes were identified: medical and social factors influencing engagement (fear of treatment and lack of knowledge, HCV relevance and competing priorities), adverse impact of HCV on health and wellness, positive experience of prison life and health care and the transformative clinical and non-clinical changes associated with HCV treatment and cure. Findings suggest that prison release was associated with multiple stressors including homelessness and drug dependence which quickly eroded the health benefits gained during incarceration. The study generated a substantive theory of the need to increase the importance of HCV care among the routine competing priorities associated with the lives of PWID. HCV infected prisoners often lead complex lives and understanding their journeys through the HCV continuum can inform the development of meaningful HCV care pathways. Many challenges exist to optimising HCV treatment uptake in this group and incarceration is an opportunity to successfully engage HCV infected prisoners who underutilise and are underserved by community-based medical services. Support and linkage to care on release is essential to optimising HCV management.

Klíčová slova:

Biology and life sciences – Organisms – Viruses – RNA viruses – Flaviviruses – Hepacivirus – Hepatitis C virus – Microbiology – Medical microbiology – Microbial pathogens – Viral pathogens – Immunodeficiency viruses – HIV – Retroviruses – Lentivirus – Medicine and health sciences – Pathology and laboratory medicine – Pathogens – Pharmaceutics – Drug therapy – Diagnostic medicine – HIV diagnosis and management – Pharmacology – Behavioral pharmacology – Drug dependence – Health care – Health care providers – Nurses – Social sciences – Law and legal sciences – Criminal justice system – Prisons – Prisoners – People and places – Population groupings – Professions – Medical personnel


Zdroje

1. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais D Des, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. Hepatology 2013;58:1215–24. doi: 10.1002/hep.26387 23504650

2. Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016;388:1089–102. doi: 10.1016/S0140-6736(16)30466-4 27427453

3. World Health Organisation. Prisons and health 2014:207.

4. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: A meta-analysis. J Epidemiol Community Health 2008;62:305–13. doi: 10.1136/jech.2006.051599 18339822

5. Rumble C, Pevalin DJ, OMoore É. Routine testing for blood-borne viruses in prisons: A systematic review. Eur J Public Health 2015;25:1078–88. doi: 10.1093/eurpub/ckv133 26219884

6. Midgard H, Weir A, Palmateer N, Lo Re V, Pineda JA, Macías J, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol 2016;65:S33–45. doi: 10.1016/j.jhep.2016.07.012 27641987

7. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM). Curr Opin HIV AIDS 2015;10:374–80. doi: 10.1097/COH.0000000000000179 26248124

8. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and Facilitators of Hepatitis C Testing, Management, and Treatment Among Current and Former Injecting Drug Users: A Qualitative Exploration. AIDS Patient Care STDS 2010;24:753–62. doi: 10.1089/apc.2010.0142 21138381

9. Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, et al. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research. vol. 25. 2014. doi: 10.1016/j.drugpo.2013.11.004 24332457

10. Yap L, Carruthers S, Thompson S, Cheng W, Jones J, Simpson P, et al. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One 2014;9:e87564. doi: 10.1371/journal.pone.0087564 24586281

11. Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. J Hepatol 2017;66:S291–2. doi: 10.1016/s0168-8278(17)30899-1

12. Grebely J, Dore GJ. Treatment of HCV in persons who inject drugs: Treatment as prevention. Clin Liver Dis 2017;9:77–80. doi: 10.1002/cld.626 30992964

13. Public Health England. Hepatitis C in the UK 2017 Report. 2017.

14. WHO 2017. Global Hepatitis Report 2017, World Health Organization. Geneva: 2017.

15. Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, et al. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction 2017;112:1290–9. doi: 10.1111/add.13764 28107585

16. Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T, et al. Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. Int J Drug Policy 2017;47:26–33. doi: 10.1016/j.drugpo.2017.08.001 28888558

17. Cuadrado A, Llerena S, Cobo C, Pallás JR, Mateo M, Cabezas J, et al. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol 2018;113:1639–48. doi: 10.1038/s41395-018-0157-x 29946175

18. Redman JS, Sterling RK. Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment. Am J Gastroenterol 2018;113:1585–7. doi: 10.1038/s41395-018-0201-x 30038424

19. Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, Lewis R, et al. Demonstration of near-elimination of Hepatitis C virus among a prison population: The Lotus Glen Correctional Centre Hepatitis C Treatment Project. Clin Infect Dis 2018;67:460–3. doi: 10.1093/cid/ciy210 29538639

20. Irish Prison Service. Irish Prison Service Annual Report 2017. Dublin: 2017. https://www.irishprisons.ie/wp-content/uploads/documents_pdf/IPS-annualreport-2017.pdf.

21. Drummond A, Codd M, Donnelly N, McCausland D, Mehegan J, Daly L, et al. Study on the prevalence of drug use, including intravenous drug use, and blood-borne viruses among the Irish prisoner population. Dublin: National Advisory Committee on Drugs and Alcohol; 2014.

22. Department of Health. Hepatitis C Screening (NCEC National Clinical Guideline No. 15). Dublin: 2017.

23. Health Service Executive. National Hepatitis C Treatment Programme—Ireland’s Health Service. Health Service Executive; 2018.

24. Health Service Executive. National Hepatitis C Strategy 2011–2014. Dublin: 2012.

25. Harris M, Rhodes T. Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. Int J Drug Policy 2018;60:24–32. doi: 10.1016/j.drugpo.2018.07.015 30092546

26. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduct J 2013;10:7. doi: 10.1186/1477-7517-10-7 23651646

27. Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, et al. Facilitators of HCV treatment adherence among people who inject drugs: A systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health 2016;16:994. doi: 10.1186/s12889-016-3671-z 27645935

28. Crowley D, Van Hout MC, Murphy C, Kelly E, Lambert JS, Cullen W. Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective—A qualitative exploration. Heal Justice 2018;6. doi: 10.1186/s40352-018-0081-6

29. Khaw FM, Stobbart L, Murtagh MJ. ‘I just keep thinking I haven’t got it because I’m not yellow’: A qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health 2007;7:98. doi: 10.1186/1471-2458-7-98 17555573

30. Lafferty L, Rance J, Grebely J, Lloyd AR, Dore GJ, Treloar C, et al. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. J Viral Hepat 2018;25:1526–32. doi: 10.1111/jvh.12987 30141261

31. Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, et al. Hepcare Europe—bridging the gap in the treatment of hepatitis C: study protocol. Expert Rev Gastroenterol Hepatol 2018;12:303–14. doi: 10.1080/17474124.2018.1424541 29300496

32. Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. Chicago: Aldine Publshing; 1967.

33. McDonnell A, Van Hout MC. Maze and minefield: a grounded theory of opiate self-detoxification in rural Ireland 2010.

34. European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction. Systematic review on active case finding of communicable diseases in prison settings. Stockholm: 2017. doi: 10.2900/348536

35. Awenat YF, Moore C, Gooding PA, Ulph F, Mirza A, Pratt D. Improving the quality of prison research: A qualitative study of ex-offender service user involvement in prison suicide prevention research. Heal Expect 2018;21:100–9. doi: 10.1111/hex.12590 28640480

36. Treloar C, Rance J, Haber P, Bath N, Day C, Dore G, et al. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. Int J Drug Policy 2014;25:865–70. doi: 10.1016/j.drugpo.2014.01.011 24559604

37. Bagnall AM, South J, Hulme C, Woodall J, Vinall-Collier K, Raine G, et al. A systematic review of the effectiveness and cost-effectiveness of peer education and peer support in prisons. BMC Public Health 2015;15:290. doi: 10.1186/s12889-015-1584-x 25880001

38. Harris M, Ward E, Gore C. Finding the undiagnosed: A qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. J Viral Hepat 2016;23:479–86. doi: 10.1111/jvh.12513 26924296

39. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014;61:S58–68. doi: 10.1016/j.jhep.2014.07.012 25443346

40. Bajpai M, Gupta E, Choudhary A. Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014;8:19. doi: 10.4103/0973-6247.126683 24678168

41. Raphael S. Crime, Incarceration, and Poverty. Oxford University Press; 2012. doi: 10.1093/oxfordhb/9780195393781.013.0021

42. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet 2018;391:241–50. doi: 10.1016/S0140-6736(17)31869-X 29137869

43. Nijhawan AE. Infectious Diseases and the Criminal Justice System. Am J Med Sci 2016;352:399–407. doi: 10.1016/j.amjms.2016.05.020 27776722

44. Centre for Disease Prevention E, Kreisel ed U. Public health guidance on active case finding of communicable diseases in prison settings Prevention and control of communicable diseases in prison settings. Stockholm and Lisbon: 2018. doi: 10.2900/619331

45. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis c in the custodial setting. Clin Infect Dis 2013;56:1078–84. doi: 10.1093/cid/cis1202 23362288

46. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis 2016;16:1409–22. doi: 10.1016/S1473-3099(16)30208-0 27615026

47. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol 1992;47:1102–14. 1329589

48. Asher AK, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, Page KA. Clinicians’ Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs. Subst Use Misuse 2016;51:1218–23. doi: 10.3109/10826084.2016.1161054 27219274

49. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Ann Intern Med 2015;163:215. doi: 10.7326/M15-0406 26120969

50. Park H, Wang W, Henry L, Nelson DR. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States. Hepatology 2019;69:1032–45. doi: 10.1002/hep.30303 30289989

51. Greer AM, Amlani A, Pauly B, Burmeister C, Buxton JA. Participant, peer and PEEP: Considerations and strategies for involving people who have used illicit substances as assistants and advisors in research. BMC Public Health 2018;18:834. doi: 10.1186/s12889-018-5765-2 29976169

52. Henderson C, Madden A, Kelsall J. ‘Beyond the willing & the waiting’—The role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy 2017;50:111–5. doi: 10.1016/j.drugpo.2017.08.004 28927831

53. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017;112:1302–14. doi: 10.1111/add.13783 28257600

54. Jacomet C, Guyot-Lénat A, Bonny C, Henquell C, Rude M, Dydymski S, et al. Addressing the challenges of chronic viral infections and addiction in prisons: The PRODEPIST study. Eur J Public Health 2016;26:122–8. doi: 10.1093/eurpub/ckv183 26454876

55. Hedrich D, Alves P, Farrell M, Stöver H, Møller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: A systematic review. Addiction 2012;107:501–17. doi: 10.1111/j.1360-0443.2011.03676.x 21955033

56. Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 2013;159:592–600. doi: 10.7326/0003-4819-159-9-201311050-00005 24189594

57. Bukten A, Stavseth MR, Skurtveit S, Tverdal A, Strang J, Clausen T. High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction 2017;112:1432–9. doi: 10.1111/add.13803 28319291

58. Dong KR, Must A, Tang AM, Beckwith CG, Stopka TJ. Competing priorities that rival health in adults on probation in Rhode Island: Substance use recovery, employment, housing, and food intake. BMC Public Health 2018;18. doi: 10.1186/s12889-018-5201-7 29482529

59. O’Donnell P, Tierney E, O’Carroll A, Nurse D, MacFarlane A. Exploring levers and barriers to accessing primary care for marginalised groups and identifying their priorities for primary care provision: A participatory learning and action research study. Int J Equity Health 2016;15. doi: 10.1186/s12939-016-0487-5 27912783

60. How can health services effectively meet the health needs of homeless people? n.d.

61. Nickasch B, Marnocha SK. Healthcare experiences of the homeless. J Am Acad Nurse Pract 2009;21:39–46. doi: 10.1111/j.1745-7599.2008.00371.x 19125894


Článek vyšel v časopise

PLOS One


2019 Číslo 9
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Svět praktické medicíny 1/2024 (znalostní test z časopisu)
nový kurz

Koncepce osteologické péče pro gynekology a praktické lékaře
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Význam metforminu pro „udržitelnou“ terapii diabetu
Autoři: prof. MUDr. Milan Kvapil, CSc., MBA

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#